Novan — Investor Presentation (February 2021)
23 slides from Novan's investor presentation, Feb 25, 2021
Slide 1: Corporate Presentation
Nitric Oxide-Based Medicine novan.com NASDAQ: NOVN Corporate Presentation February 24, 2021 Exhibit 99.2
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements including, but not limited to, statements related to the potential therapeutic value of our NITRICIL™ platform technology, our pharmaceutical development of nitric oxide-releasing product candidates, our intention to ad
Slide 3: Ongoing pivotal Phase 3 study with data targeted before the end of Q2 2021
Ongoing pivotal Phase 3 study with data targeted before the end of Q2 2021 3
Slide 4: Investment Opportunity
Investment Opportunity 4 Company’s First Potential NDA Filing Targeted No Later Than Q3 2022 NITRICIL™ Platform Significant Market Opportunity Pipeline Expansion Opportunities ~3.4 million1 Lead program, SB206 ongoing pivotal Phase 3 for treatment of molluscum Leveraging nitric oxide’s naturally occ
Slide 5: Priority Development Pipeline
Priority Development Pipeline 5 Product Candidate Indication Pre-IND Phase 1 Phase 2 Phase 3 Approval Program Highlight DERMATOLOGY SB206 Molluscum Target Reporting Topline Results before the end of Q2 2021 INFECTIOUS DISEASE SB019 Coronavirus First Demonstration of Antiviral Effect of NO Against SA
Slide 6: NITRICIL™: Nitric oxide (NO) for therapeutic innovation
NITRICIL™ Nitric oxide (NO) for therapeutic innovation 6
Slide 7: Nitric Oxide (NO): Naturally Occurring Antiviral and Immunomodulatory Effects
Nitric Oxide (NO) 7 Naturally Occurring Antiviral and Immunomodulatory Effects Colasanti, M. et al. S-Nitrosylation of Viral Proteins: Molecular Bases for Antiviral Effect of Nitric Oxide IUBMB Life; 1999 (48) 25-31. Kroen, KD. J Clin Invest. 1993;91(6):2446- 2452.; Karupiah, G; et al. Science. 1993
Slide 8: Tunable Dosing Enables Proprietary Formulations That Target Each Indication
8 Tunable Dosing Enables Proprietary Formulations That Target Each Indication NITRICIL™ Proprietary Nitric Oxide Based Technology Platform Generates Macromolecular New Chemical Entities (NCEs) 8006004002000 100 80 60 40 20 0 Time (min) % N O R el ea se NVN4428 NVN1000 t1/2 =2.3 min t1/2 =118 min Cum
Slide 9: SB206: Lead Program
SB206: Lead Program 9 Ongoing pivotal Phase 3 study for treatment of molluscum
Slide 10: SB206: Berdazimer Sodium Topical Antiviral Gel
10 New Chemical Entity Patients treated to date: >3,400 Compelling safety profile Macromolecule comprised of a polysiloxane backbone with covalently bound N-diazeniumdiolate NO donors SB206: Berdazimer Sodium Topical Antiviral Gel for the Treatment of Viral Skin Infections IP until 2035 Re al -T im
Slide 11: No FDA-Approved Treatments for Molluscum
11 No FDA-Approved TreatmentsMolluscum Contagious skin infection caused by the molluscipoxvirus, a double- stranded DNA virus Current treatment options are limited: • Off-label Rx/OTC• Physical procedures ~70% of patients below the age of 10 Average time to resolution 13 Months ~3.4 million prevalen
Slide 12: Development Pathway Towards Potential Approval
Development Pathway Towards Potential Approval 12 Potential NDA Filing Targeted No Later Than Q3 2022 B-SIMPLE2 Completed B-SIMPLE4 Topline Results Targeted Q2 2021 B-SIMPLE1 Completed Key findings from immense body of data and external experts guided the design of the B-SIMPLE program 352 Subject
Slide 13: B-SIMPLE1 and B-SIMPLE2 Integrated Analysis
B-SIMPLE1 and B-SIMPLE2 13 Integrated Analysis Demonstrated Statistically Significant (p=0.038) Complete Clearance Rate (27.9%) vs. Vehicle (20.9%) at Week 12 B-SIMPLE1: 352 Subjects B-SIMPLE2: 355 Subjects 0.0% 4.3% 10.3% 21.6% 0.4% 4.7% 15.3% 25.8% 0% 5% 10% 15% 20% 25% 30% 35% Week 2 Week 4 Week
Slide 14: B-SIMPLE4 Pivotal Phase 3 Study Design in Molluscum
Treatment 12 Weeks Follow-up at Week 24 14 B-SIMPLE4 Pivotal Phase 3 Study Design in Molluscum Study Design Based on Learnings from B-SIMPLE1 and B-SIMPLE2: One and two-subject household stratification Inflammation of molluscum lesions added as a stratification factor1 Additional patient and caregiv
Slide 15: SB206 Commercialization Strategy
SB206 Commercialization Strategy 15 Preparing for Success Evaluating All Strategic Options Novan Commercializes Secure Commercialization Partner Co-Commercialize with Partner
Slide 16: Coronavirus (COVID-19) Program
16 Coronavirus (COVID-19) Program Potential IND filing targeted in 2021 Results from in vitro assessment of concentrations as low as 0.75 mg/mL demonstrated berdazimer sodium reduced 90% of virus after repeat dosing, once daily Engaged Catalent, a global leader in providing integrated services, supe
Slide 17: Companion Animal Health Program
Companion Animal Health Program 17 Commenced Exploratory Work to Evaluate NO Application in Adjacent Market Engaged third-party animal health experts to determine technical feasibility and market potential Initial formulation development to assess viability in progress Upon positive proof of concept
Slide 18: Pipeline Expansion Opportunities
Pipeline Expansion Opportunities 18 Ongoing In-Depth Review for Pipeline Prioritization Product Candidates Indication Pre-IND Phase 1 Phase 2 Phase 3 Program Highlight DERMATOLOGY SB204 Acne Vulgaris Two Phase 3’s completed; One confirmatory Phase 3 needed; Protocol finalized SB208 Tinea Pedis Phase
Slide 19: Corporate Overview
Corporate Overview 19
Slide 20: Financial Profile
Financial Profile Nasdaq: NOVN 20 1. Out of 200,000,000 total common stock authorized per certificate of incorporation. 2. Based on February 10, 2021 closing price of $1.96. 3. Based on Management’s projections and planned development and operating activities described in the Company’s December 31,
Slide 21: Upcoming Targeted Milestones
Upcoming Targeted Milestones 21 September 2020: Selection of NCE for Animal Health Pipeline October 2020: Coronavirus - Reported Results Demonstrating In Vitro Antiviral Effect September 2020: First Patient Dosed September 2020: Commenced Study February 2021: Completed Enrollment SB206 B-S
Slide 22: Near Term Inflection Point: Broad Pipeline
Near Term Inflection Point: Broad Pipeline 22 Topline Results From Pivotal B-SIMPLE4 Phase 3 Study in Molluscum Targeted Before the End of Q2 2021 Proprietary NITRICIL™ Platform: Harnessing the antiviral and immunomodulatory power of nitric oxide Fueling a pipeline with multiple growth opportunities
Slide 23: Investor Relations
Nitric Oxide-Based Medicine Investor Relations JTC Team 833.475.8247 novn@jtcir.com novan.com NASDAQ: NOVN